Search Tag: breast cancer
2025 15 Oct
Minimally invasive image-guided biopsy is central to diagnosing suspicious breast lesions while reducing complications, costs and cosmetic impact compared with diagnostic surgery. Multiple techniques are in routine use—fine-needle aspiration (FNA), core-needle biopsy (CNB) and vacuum-assisted biopsy (VAB)—and can be performed under ultrasound...Read more
2025 15 Oct
Minimally invasive image-guided biopsy is central to diagnosing suspicious breast lesions while reducing complications, costs and cosmetic impact compared with diagnostic surgery. Multiple techniques are in routine use—fine-needle aspiration (FNA), core-needle biopsy (CNB) and vacuum-assisted biopsy (VAB)—and can be performed under ultrasound...Read more
2025 15 Oct
Minimally invasive image-guided biopsy is central to diagnosing suspicious breast lesions while reducing complications, costs and cosmetic impact compared with diagnostic surgery. Multiple techniques are in routine use—fine-needle aspiration (FNA), core-needle biopsy (CNB) and vacuum-assisted biopsy (VAB)—and can be performed under ultrasound...Read more
2025 15 Oct
Minimally invasive image-guided biopsy is central to diagnosing suspicious breast lesions while reducing complications, costs and cosmetic impact compared with diagnostic surgery. Multiple techniques are in routine use—fine-needle aspiration (FNA), core-needle biopsy (CNB) and vacuum-assisted biopsy (VAB)—and can be performed under ultrasound...Read more
2025 02 Sep
Population-based breast cancer screening programmes have been effective in reducing mortality across Europe, largely through the detection of smaller, node-negative tumours at earlier stages. However, conventional mammography faces challenges such as limited sensitivity, a shortage of radiologists and variation in diagnostic accuracy. Artificial...Read more
2025 02 Sep
Population-based breast cancer screening programmes have been effective in reducing mortality across Europe, largely through the detection of smaller, node-negative tumours at earlier stages. However, conventional mammography faces challenges such as limited sensitivity, a shortage of radiologists and variation in diagnostic accuracy. Artificial...Read more
2025 02 Sep
Population-based breast cancer screening programmes have been effective in reducing mortality across Europe, largely through the detection of smaller, node-negative tumours at earlier stages. However, conventional mammography faces challenges such as limited sensitivity, a shortage of radiologists and variation in diagnostic accuracy. Artificial...Read more
2025 20 Jul
The integration of artificial intelligence into breast cancer screening holds promise for addressing workforce shortages and enhancing diagnostic accuracy. While previous studies have demonstrated that AI decision support can improve sensitivity without compromising specificity or reading time, its influence on radiologists’ visual search strategies...Read more
2025 20 Jul
The integration of artificial intelligence into breast cancer screening holds promise for addressing workforce shortages and enhancing diagnostic accuracy. While previous studies have demonstrated that AI decision support can improve sensitivity without compromising specificity or reading time, its influence on radiologists’ visual search strategies...Read more
2025 20 Jul
The integration of artificial intelligence into breast cancer screening holds promise for addressing workforce shortages and enhancing diagnostic accuracy. While previous studies have demonstrated that AI decision support can improve sensitivity without compromising specificity or reading time, its influence on radiologists’ visual search strategies...Read more
2025 20 Jul
The integration of artificial intelligence into breast cancer screening holds promise for addressing workforce shortages and enhancing diagnostic accuracy. While previous studies have demonstrated that AI decision support can improve sensitivity without compromising specificity or reading time, its influence on radiologists’ visual search strategies...Read more
2025 30 Jun
In a strategic move to improve patient outcomes in breast cancer, Affidea , a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging. Breast cancer...Read more
2025 30 Jun
In a strategic move to improve patient outcomes in breast cancer, Affidea , a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging. Breast cancer...Read more
2025 30 Jun
In a strategic move to improve patient outcomes in breast cancer, Affidea , a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging. Breast cancer...Read more
2025 20 Jun
Magnetic resonance imaging (MRI) remains the most sensitive tool for breast cancer detection, particularly in women with dense breast tissue. Its growing application spans screening high-risk populations, staging malignancies and assessing treatment response. However, long acquisition times and susceptibility to image artefacts have limited broader...Read more
2025 20 Jun
Magnetic resonance imaging (MRI) remains the most sensitive tool for breast cancer detection, particularly in women with dense breast tissue. Its growing application spans screening high-risk populations, staging malignancies and assessing treatment response. However, long acquisition times and susceptibility to image artefacts have limited broader...Read more
2025 30 May
Affidea has acquired Uroviva, Switzerland’s top urology network, nearly doubling its size and expanding integrated oncology services. The move strengthens Affidea’s breast and prostate cancer pathways, combining diagnostics, treatment and monitoring. Uroviva’s expertise and advanced technologies will support a seamless, patient-centred care model...Read more
2025 30 May
Affidea has acquired Uroviva, Switzerland’s top urology network, nearly doubling its size and expanding integrated oncology services. The move strengthens Affidea’s breast and prostate cancer pathways, combining diagnostics, treatment and monitoring. Uroviva’s expertise and advanced technologies will support a seamless, patient-centred care model...Read more
2025 22 May
Breast cancer is the most common malignancy among women worldwide, with early detection playing a pivotal role in improving survival outcomes. Mammography remains the gold standard for breast cancer screening, but its interpretation is fraught with challenges, including variability in radiologist expertise and the risk of diagnostic error. Artificial...Read more
2025 22 May
Breast cancer is the most common malignancy among women worldwide, with early detection playing a pivotal role in improving survival outcomes. Mammography remains the gold standard for breast cancer screening, but its interpretation is fraught with challenges, including variability in radiologist expertise and the risk of diagnostic error. Artificial...Read more
2025 22 May
Breast cancer is the most common malignancy among women worldwide, with early detection playing a pivotal role in improving survival outcomes. Mammography remains the gold standard for breast cancer screening, but its interpretation is fraught with challenges, including variability in radiologist expertise and the risk of diagnostic error. Artificial...Read more
2025 03 Apr
Strategic acquisition creates a leading oncology platform in Switzerland, with super-specialisation in breast and prostate cancer and an integrated care pathway Affidea Group, a leading pan-European provider of specialist healthcare services including cancer care, advanced diagnostic imaging and community-based polyclinics, today announced...Read more
2025 04 Feb
Affidea Group, the pan-European provider of specialist healthcare services, including cancer care, advanced diagnostic imaging and community-based polyclinics , announced today the acquisition of Instituts für histologische und zytologische Diagnostik AG, in Switzerland. This acquisition adds two high-quality pathology laboratories...Read more
2024 25 Aug
Breast cancer (BC) remains the most prevalent malignancy among women globally. The classification and accurate identification of human epidermal growth factor receptor 2 (HER2) status are critical for determining appropriate treatment plans, particularly for targeted therapies. Traditionally, HER2 status is assessed through invasive methods such...Read more
2024 06 Jun
Radial scars are abnormal growths in the breast tissue with a characteristic appearance on histopathology. They are increasingly being detected due to improved imaging techniques. Historically, they were often surgically removed due to concerns about potential cancer risk, but recent studies show variable rates of cancer upstaging following surgery....Read more
2024 29 Apr
Hologic, Inc., a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments. “Endomag’s suite of solutions...Read more
2024 29 Apr
Hologic, Inc., a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments. “Endomag’s suite of solutions...Read more
2024 29 Jan
A groundbreaking study led by Dr Dooman Arefan from the University of Pittsburgh has unveiled a promising method for predicting breast cancer recurrence risk. The research, published in Radiology , sheds light on how quantitative background parenchymal enhancement (BPE) measurements at dynamic contrast-enhanced MRI (DCE-MRI) could predict the...Read more
2024 29 Jan
A groundbreaking study led by Dr Dooman Arefan from the University of Pittsburgh has unveiled a promising method for predicting breast cancer recurrence risk. The research, published in Radiology , sheds light on how quantitative background parenchymal enhancement (BPE) measurements at dynamic contrast-enhanced MRI (DCE-MRI) could predict the...Read more
2024 22 Jan
b-rayZ, Swiss innovator in AI-powered medical imaging solution s, proudly announces the receipt of the CE mark for the groundbreaking DANAI technology. Seamlessly integrated into the comprehensive breast diagnostic suites, b-box plus, DANAI empowers breast cancer detection, density assessment and quality-controlled breast positioning. DANAI marks...Read more